CN1850078B - 一种抗血小板凝集药物注射液及其制备方法 - Google Patents
一种抗血小板凝集药物注射液及其制备方法 Download PDFInfo
- Publication number
- CN1850078B CN1850078B CN2006100130829A CN200610013082A CN1850078B CN 1850078 B CN1850078 B CN 1850078B CN 2006100130829 A CN2006100130829 A CN 2006100130829A CN 200610013082 A CN200610013082 A CN 200610013082A CN 1850078 B CN1850078 B CN 1850078B
- Authority
- CN
- China
- Prior art keywords
- injection
- water
- recipe quantity
- glucose
- platelet aggregation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002347 injection Methods 0.000 title claims abstract description 43
- 239000007924 injection Substances 0.000 title claims abstract description 43
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title claims description 8
- 230000000702 anti-platelet effect Effects 0.000 title claims description 6
- 239000003146 anticoagulant agent Substances 0.000 title claims description 6
- 238000000034 method Methods 0.000 title abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000243 solution Substances 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 16
- 239000008103 glucose Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 11
- 238000003756 stirring Methods 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000001802 infusion Methods 0.000 claims abstract description 6
- 229960004929 tirofiban hydrochloride Drugs 0.000 claims description 21
- HWAAPJPFZPHHBC-FGJQBABTSA-N tirofiban hydrochloride Chemical compound O.Cl.C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 HWAAPJPFZPHHBC-FGJQBABTSA-N 0.000 claims description 21
- 239000008215 water for injection Substances 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000012982 microporous membrane Substances 0.000 claims description 4
- 238000005262 decarbonization Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 10
- 229910052799 carbon Inorganic materials 0.000 abstract description 5
- 238000011049 filling Methods 0.000 abstract description 3
- 238000007789 sealing Methods 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 229960004441 tyrosine Drugs 0.000 abstract description 2
- 230000004520 agglutination Effects 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 25
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 13
- 229960001031 glucose Drugs 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000013618 particulate matter Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000003182 parenteral nutrition solution Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 229960003425 tirofiban Drugs 0.000 description 4
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000006101 laboratory sample Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- -1 338-342).Therefore Substances 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100130829A CN1850078B (zh) | 2006-01-20 | 2006-01-20 | 一种抗血小板凝集药物注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100130829A CN1850078B (zh) | 2006-01-20 | 2006-01-20 | 一种抗血小板凝集药物注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1850078A CN1850078A (zh) | 2006-10-25 |
CN1850078B true CN1850078B (zh) | 2010-09-08 |
Family
ID=37131590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100130829A Expired - Fee Related CN1850078B (zh) | 2006-01-20 | 2006-01-20 | 一种抗血小板凝集药物注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1850078B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101368897B (zh) * | 2008-09-08 | 2011-01-26 | 西王集团有限公司 | 无水葡萄糖滤膜滤速检测方法 |
CN110988158A (zh) * | 2019-11-25 | 2020-04-10 | 鲁南制药集团股份有限公司 | 一种盐酸替罗非班注射液有关物质的检测方法 |
CN111937858A (zh) * | 2020-07-06 | 2020-11-17 | 晶准生物医学(深圳)有限公司 | 抗凝组合物、真空采血管 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1634054A (zh) * | 2004-10-29 | 2005-07-06 | 武汉远大制药集团股份有限公司 | 一种抑制血小板凝聚的注射液及其制备方法 |
CN1686127A (zh) * | 2005-03-24 | 2005-10-26 | 武汉远大制药集团股份有限公司 | 一种抑制血小板凝聚的注射用粉针及其制备方法 |
-
2006
- 2006-01-20 CN CN2006100130829A patent/CN1850078B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1634054A (zh) * | 2004-10-29 | 2005-07-06 | 武汉远大制药集团股份有限公司 | 一种抑制血小板凝聚的注射液及其制备方法 |
CN1686127A (zh) * | 2005-03-24 | 2005-10-26 | 武汉远大制药集团股份有限公司 | 一种抑制血小板凝聚的注射用粉针及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1850078A (zh) | 2006-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102125519B (zh) | 稳定的盐酸替罗非班注射液及其制备方法 | |
CN101411710A (zh) | 培美曲塞二钠冻干粉针剂及其制备方法 | |
CN106963759A (zh) | 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3‑奎宁环酮衍生物的水溶液 | |
CN1850078B (zh) | 一种抗血小板凝集药物注射液及其制备方法 | |
CN104414977A (zh) | 一种注射用青蒿琥酯和l-精氨酸组合物及其制备方法 | |
CN102600072B (zh) | 盐酸替罗非班注射液及其制备方法 | |
CN105362235B (zh) | 阿莫西林钠克拉维酸钾的复方药物组合物及其制备方法 | |
CN104784113B (zh) | 一种含有利奈唑胺的组合物及其制备方法 | |
CN100386079C (zh) | 一种抑制血小板凝聚的注射用粉针及其制备方法 | |
CN102038680A (zh) | 一种药用组合物 | |
CN102846561A (zh) | 一种供注射用的奥扎格雷钠药物组合物 | |
CN104922080A (zh) | 治疗消化系统疾病的药物艾普拉唑钠冻干粉针剂组合物 | |
CN102871961B (zh) | 一种含替罗非班的注射液 | |
CN1322863C (zh) | 一种抑制血小板凝聚的注射液及其制备方法 | |
CN102552210B (zh) | 一种恩替卡韦胶囊组合物及其制备方法 | |
CN103027890B (zh) | 供注射用的布洛芬药物组合物 | |
CN102258507A (zh) | 含有布洛芬的药物组合物及其制备方法和应用 | |
CN101716138B (zh) | 一种含有盐酸替罗非班的注射液 | |
CN103877579B (zh) | 一种含有法莫替丁的药物组合物及其制剂 | |
CN102824340A (zh) | 布洛芬组合物注射液及其制备方法 | |
CN117180189B (zh) | 一种舒必利注射液及其制备方法、应用 | |
CN102988306B (zh) | 一种含有奥扎格雷钠化合物的药物组合物 | |
CN102755290B (zh) | 一种含有布洛芬的药物组合物 | |
CN106943342A (zh) | 一种含有阿加曲班的药物组合物 | |
Onuki et al. | A 5% glucose infusion fluid provokes significant precipitation of phenytoin sodium injection via interruption of the cosolvent effect of propylene glycol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIBET LINZHI BAISHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANKAI YUNGONG PHARMACEUTICAL SCIENCE-TECHNOLOGY CO., LTD., TIANJIN Effective date: 20130822 Owner name: NAIKAI SHARE PHARMACEUTICAL CO., LTD. Effective date: 20130822 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300071 NANKAI, TIANJIN TO: 850400 NYINGCHI PREFECTURE, TIBET AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130822 Address after: 850400 Tibet autonomous region Linzhi region Biotechnology Industry Park Patentee after: Tibet Linzhi Baisheng Pharmaceutical Co., Ltd. Patentee after: Naikai Share Pharmaceutical Co., Ltd. Address before: 300071 teaching instrument building, Southwest Village, Nankai University, Tianjin Patentee before: Nankai Yungong Pharmaceutical Science-Technology Co., Ltd., Tianjin |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 850000 Tibet autonomous region Linzhi region Biotechnology Industry Park Patentee after: Tibet Linzhi Baisheng Pharmaceutical Co., Ltd. Patentee after: Tongliao Huabang Pharmaceutical Co Ltd Address before: 850000 Tibet autonomous region Linzhi region Biotechnology Industry Park Patentee before: Tibet Linzhi Baisheng Pharmaceutical Co., Ltd. Patentee before: Naikai Share Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100908 Termination date: 20190120 |
|
CF01 | Termination of patent right due to non-payment of annual fee |